Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma

Cancer

Volumn 121, Issue 20, 2015, Pages 3659-3667

  Tseng, William W ^a,b   Zhou, Shouhao ^c   To, Christina A ^a   Thall, Peter F ^c   Lazar, Alexander J ^c   Pollock, Raphael E ^d   Lin, Patrick P ^c   Cormier, Janice N ^c   Lewis, Valerae O ^c   Feig, Barry W ^c   Hunt, Kelly K ^c   Ballo, Matthew T ^e   Patel, Shreyaskumar ^c   Pisters, Peter W T ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

gemcitabine; neoadjuvant; radiation; sarcoma; toxicity

Indexed keywords

DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; DEOXYCYTIDINE; RADIOSENSITIZING AGENT;

ADULT; AGED; ARTICLE; BAYESIAN LEARNING; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DERMATITIS; DISTANT METASTASIS FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEASIBILITY STUDY; FEVER; FOLLOW UP; HEPATITIS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIMB; LIVER TOXICITY; LOCAL RECURRENCE FREE SURVIVAL; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RADIATION DOSE; SEROMA; SIMULATION; SOFT TISSUE SARCOMA; SURVIVAL RATE; TRUNK; TUMOR VOLUME; VOMITING; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; BAYES THEOREM; CLINICAL TRIAL; DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOLOGY; PROCEDURES; RADIATION DOSE FRACTIONATION; SARCOMA; SURVIVAL; TREATMENT OUTCOME;

ADULT; BAYES THEOREM; CHEMORADIOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; EXTREMITIES; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; RADIATION-SENSITIZING AGENTS; SARCOMA; SURVIVAL ANALYSIS; TORSO; TREATMENT OUTCOME;

EID: 84943545624     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29544     Document Type: Article

References (30)

1. Clark MA, Fisher C, Judson I, Thomas JM,. Soft-tissue sarcomas in adults. N Engl J Med. 2005; 353: 701-711.
2. Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY, Hohenberger P,. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol. 2011; 22: 1266-1272.
3. Hensley ML,. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Curr Opin Oncol. 2010; 22: 356-361.
4. Patel SR, Gandhi V, Jenkins J, et al., Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001; 19: 3483-3489.
5. Maki RG, Wathen JK, Patel SR, et al., Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration Study 002. J Clin Oncol. 2007; 25: 2755-2763.
6. Pautier P, Floquet A, Penel N, et al., Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist. 2012; 17: 1213-1220.
7. Pauwels B, Korst AE, Lardon F, Vermorken JB,. Combined modality therapy of gemcitabine and radiation. Oncologist. 2005; 10: 34-51.
8. El Deen DA, Toson EA, El Morsy SM,. Gemcitabine-based induction chemotherapy and concurrent with radiation in advanced head and neck cancer. Med Oncol. 2012; 29: 3367-3373.
9. Kim EJ, Ben-Josef E, Herman JM, et al., A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013; 119: 2692-2700.
10. Mornex F, Girard N,. Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art. Ann Oncol. 2006; 17: 1743-1747.
11. Milas L, Fujii T, Hunter N, et al., Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 1999; 59: 107-114.
12. Murphy JD, Lucas DR, Somnay YR, Hamstra DA, Ray ME,. Gemcitabine-mediated radiosensitization of human soft tissue sarcoma. Transl Oncol. 2008; 1: 50-56.
13. Pisters PW, Ballo MT, Patel SR,. Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol. 2002; 9: 535-542.
14. Reynoso D, Subbiah V, Trent JC, et al., Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach. J Surg Oncol. 2010; 101: 327-333.
15. Bekele BN, Thall PF,. Dose-finding based on multiple toxicities in a soft tissue sarcoma trial. J Am Stat Assoc. 2004; 99: 26-35.
16. Cheung YK,. Designs for phase I trials. In:, Harrington D, ed. Designs for Clinical Trials: Perspectives on Current Issues. New York, NY: Springer; 2012: 1-27.
17. Ezzalfani M, Zohar S, Qin R, Mandrekar SJ, Deley MC,. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities. Stat Med. 2013; 32: 2728-2746.
18. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
19. Mantel N,. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163-170.
20. Gelman A, Carlin JB, Stern HS, Rubin DB,. Bayesian Data Analysis. New York, NY: Chapman & Hall/CRC; 2004.
21. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
22. Yuan Z, Chappell R, Bailey H,. The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach. Biometrics. 2007; 63: 173-179.
23. Chen Z, Krailo MD, Azen SP, Tighiouart M,. A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in phase I clinical trials. Contemp Clin Trials. 2010; 31: 473-482.
24. Lee SM, Hershman DL, Martin P, Leonard JP, Cheung YK,. Toxicity burden score: a novel approach to summarize multiple toxic effects. Ann Oncol. 2012; 23: 537-541.
25. Canter RJ, Martinez SR, Tamurian RM, et al., Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol. 2010; 17: 2578-2584.
26. Shah D, Borys D, Martinez SR, et al., Complete pathologic response to neoadjuvant radiotherapy is predictive of oncological outcome in patients with soft tissue sarcoma. Anticancer Res. 2012; 32: 3911-3915.
27. Eilber FC, Rosen G, Eckardt J, et al., Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001; 19: 3203-3209.
28. Pisters PW, Patel SR, Prieto VG, et al., Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol. 2004; 22: 3375-3380.
29. Canter RJ, Borys D, Olusanya A, et al., Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. 2014; 21: 1616-1623.
30. Meyer JM, Perlewitz KS, Hayden JB, et al., Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res. 2013; 19: 6902-6911.